Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET

Company Participants

Kevin Gardner - Managing Director-LifeSci Advisors

Ted White - President & Chief Executive Officer

Joe Bonaccorso - Chief Commercial Officer

Terry Kohler - Chief Financial Officer

Gary Goldenberg - Chief Medical Officer

Conference Call Participants

Stacy Ku - TD Cowen

Oren Livnat - H.C. Wainwright

Kemp Dolliver - Brookline Capital Markets

Operator

Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.

I'll now turn the call over to our host Kevin Gardner of LifeSci Advisors. You may begin your conference.

Kevin Gardner

Thank you, operator. Hello, everyone and welcome to Verrica Pharmaceuticals fourth quarter and year end 2023 corporate update and earnings conference call.

With me on the line this morning are Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals; Joe Bonaccorso, Chief Commercial Officer; Terry Kohler, Chief Financial Officer; Dr. Gary Goldenberg, Verrica's Chief Medical Officer; and Chris Hayes, Verrica's Chief Legal Officer.

As a reminder, during today's call, management will make forward looking statements. These statements may include expectations related to the launch and commercialization of YCANTH for the treatment of molluscum contagiosum in the United States, regulatory development, the development of Verrica's product candidates, our expected cash runway as well as overall business strategy and planned operations.

These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. And based on those risks and uncertainties, Verrica's actual results and timing of events could differ materially from those anticipated in such forward-looking statements.

Please see the Verrica's SEC filings for important risk factors. Verrica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information future events or changes in expectations.

In addition, during today's call, we will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in addition to and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures versus their closest GAAP equivalent. Our earnings release that we issued today includes GAAP to non-GAAP reconciliations for these measures and is also available on the Investor Relations section of our website.